<![CDATA[UT MD Anderson Shares Latest Research Breakthroughs]]>

Press Release|Articles|May 8, 2026 UT MD Anderson Shares Latest Research Breakthroughs Author(s)MD Anderson Cancer Center Listen0:00 / 0:00 Key Takeaways Zongertinib achieved a 76% ORR and 15.2-month median response duration in treatment-naïve HER2-mutant advanced/metastatic NSCLC, establishing an oral targeted alternative to chemotherapy and enabling accelerated FDA approval. Abbreviated chemotherapy plus brentuximab vedotin and nivolumab in non-bulky early-stage cHL maintained high responses across risk strata while omitting two chemotherapy drugs and radiation, reducing cumulative toxicity. Conformational regulation of Dicer via epigenetic perturbations links altered cell-division control to infertility and oncogenesis, suggesting DICER1-associated tumor biology may be modulated by epigenetic states. RF-SIRF enables single-cell quantitative mapping of reversed replication forks and identifies site-specific epigenetic signatures of replication stress, informing genomic stability, aging biology, and precision-therapy response determinants. FLAG plus gemtuzumab ozogamicin or idarubicin delivered 74% five-year OS in CBF-AML, with non-randomized superiority for FLAG-GO (80% five-year OS), reinforcing a standard frontline approach.SHOW MORE The University of Texas MD Anderson Cancer Center released recent oncology research highlights. At The University of Texas MD Anderson Cancer Center, research breakthroughs are made possible through seamless collaboration between the institution’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. The studies below showcase the latest advances in cancer care, research and prevention.First-line targeted therapy shows antitumor activity in patients with advanced lung cancerRead the full release | Read the study in The New England Journal of MedicineFirst-line zongertinib showed antitumor activity in treatment-naïve patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), providing a safe and effective oral targeted treatment alternative to chemotherapy. Results from the multi-site Phase Ia/Ib Beamion LUNG-1 trial reported a 76% objective response rate (ORR), indicating tumor shrinkage in 56 of 74 patients. Responses lasted for a median duration of 15.2 months, with no progression of disease for over 14 months. This data supports the recent accelerated approval of zongertinib by the Food and Drug Administration (FDA) for the treatment of unresectable or metastatic HER2-mutant NSCLC. “We observed unprecedented response rates for this cancer subtype, and these findings led to zongertinib becoming the first FDA-approved treatment of its kind for these patients,” said principal investigator John Heymach, M.D., Ph.D., chair of Thoracic/Head and Neck Medical Oncology. “What’s particularly exciting is that just a few years ago, patients with this disease had no effective targeted therapies. Now, health care providers have a HER2-targeted treatment option that can make a meaningful difference.”Novel combination therapy yields high response rates in early-stage classical Hodgkin lymphomaRead the full release | Read the study in BloodThe combination of abbreviated chemotherapy with brentuximab vedotin and nivolumab achieved high response rates in patients with non-bulky, early-stage classical Hodgkin lymphoma (cHL). By using this combination approach, researchers of the Phase 2 trial, led by Hun Lee, M.D., associate professor of Lymphoma, were able to omit two chemotherapy drugs along with radiation therapy for these patients, a significant de-escalation of treatment.“We are pleased with these outcomes, which were consistent across both favorable- and unfavorable-risk groups,” Lee said. “Our ability to omit several medications and radiation therapy demonstrates that we can maintain or improve outcomes and reduce treatment toxicity.”Researchers identify how enzyme affects infertility and cancer progressionRead the full release | Read the study in Nature CommunicationsActivation of a specific part of the Dicer enzyme can change its shape in a way that affects its critical role in proper cell division, with implications for both cancer biology and fertility.The study, led by Swathi Arur, Ph.D., professor of Genetics, fills a major gap in understanding how the Dicer enzyme is regulated. The results open new avenues for studying how small epigenetic changes – which turn genes on or off without altering their sequence – and other disruptions in these pathways can affect Dicer’s role in a way that can contribute to both cancer progression and infertility.“These findings expand the implications of Dicer regulation beyond germline biology by suggesting that epigenetic modifications can tune its shape and the proteins it recruits, creating a potential mechanism for disease,” Arur said. “In cancer, where DICER1 dysfunction is already linked to altered cell identity and tumor progression, this raises the possibility that irregular epigenetic activity could reshape these networks in ways that promote cancer.”Imaging tool reveals novel insights into DNA replication stress responseRead the full release | Read the study in Nature CommunicationsResearchers have developed a new imaging method, known as RF-SIRF, that quantitatively detects and maps reversed DNA replication forks with single-cell resolution. The results also demonstrated a unique epigenetic code for DNA replication stress that can be further examined to understand mechanisms of genomic stability, aging and treatment response. The study was led by Katharina Schlacher, Ph.D., associate professor of Cancer Biology.“By capturing reversed DNA replication forks in their spatiotemporal context, our new assay identifies site-specific epigenetic signatures,” Schlacher said. “This technology provides a unique lens, enabling scientists to decode cancer-specific DNA replication stress dynamics and their crosstalk with inflammation and transcription programs, representing a major step in precision oncology.”FLAG-based regimen delivers strong outcomes in subtype of acute myeloid leukemiaRead the full release | Read the study in Blood Cancer DiscoveryA new analysis demonstrates that combination therapy consisting of fludarabine, cytarabine and G-CSF (FLAG) plus gemtuzumab ozogamicin (GO) or idarubicin (IDA) continues to deliver strong long-term outcomes for patients with core-binding factor acute myeloid leukemia (CBF-AML), a subtype of the disease involving a chromosomal rearrangement. The study was co-led by Gautam Borthakur, M.D., professor of Leukemia, and Jayastu Senapati, M.D., assistant professor of Leukemia. The researchers analyzed long-term outcomes from a cohort of patients treated in a Phase 2 trial. The five-year overall survival rate reached 74%, while the relapse-free survival rate was 67% for patients treated in this study. Among patients who had received GO along with FLAG (FLAG-GO), the five-year overall survival rate was superior at 80% as opposed to FLAG-IDA on non-randomized comparisons.“This is one of the highest reported five-year, relapse-free overall survival rates we have observed,” Borthakur said. “This regimen is now our standard frontline therapy for adults with core-binding factor AML, and these findings further strengthen the evidence supporting its use.”Novel tool more accurately predicts risk of Li-Fraumeni SyndromeRead the full release | Read the study in The American Journal of Human GeneticsIn a prospective validation study, researchers demonstrated that a new mathematical model, called LFSPRO, was effective in supporting genetic counselor decision-making and more accurately predicted individuals at higher risk of Li-Fraumeni Syndrome (LFS), a hereditary condition that carries a higher risk of developing multiple cancers. LFSPRO provided risk scores that significantly outperformed current criteria for genetic testing and provided valuable insights and quantifiable data for genetic counselors that more closely aligned with their clinical judgment. The study was led by Wenyi Wang, Ph.D., professor of Bioinformatics and Computational Biology, and Banu Arun, M.D., professor of Breast Medical Oncology.“Most risk prediction models are validated only in research-based cohorts, but our study demonstrates LFSPRO's performance in a real-world genetic counseling setting, where limited family history information is provided within 30 minutes and most counselees test negative,” Wang said. “Our model demonstrated substantially higher accuracy than current clinical guidelines and had strong concordance with genetic counselors' judgment.”New simulation framework DKOsim advances CRISPR-based gene to gene interaction researchRead the full release | Read the study in PLOS Computational BiologyResearchers developed Double-CRISPR Knockout Simulation (DKOsim), a novel computational framework designed to address longstanding challenges in profiling gene to gene interactions. The findings may help streamline genetic interactions detection through optimized computational methods and guide the development of next-generation dual-knockout CRISPR screens.“DKOsim provides a much-needed bridge between experimental and computational biology,” said John Paul Shen, M.D., assistant professor of Gastrointestinal Medical Oncology. “It enables scientists to systematically test a hypothesis, optimize experimental design and benchmark analytical tools under controlled conditions.”Awards and HonorsJohn Weinstein, M.D., Ph.D., professor of Bioinformatics and Computational Biology, was inducted into the 2026 Class of the International Society for Computational Biology (ISCB) Distinguished FellowsUT MD Anderson at AACRRead highlights from UT MD Anderson at the American Association for Cancer Research (AACR) Annual Meeting 2026. More information can be found at MDAnderson.org/AACR.Novel approach prevents cancer progression, spares surgery for majority of patients with precancerous oral lesionsNew platform uses machine learning to predict responses in patients with lung cancerZedoresertib and lunresertib combination shows promising antitumor activityClinical trial presentations feature advances across cancer careUT MD Anderson shares latest breakthroughs in cancer researchJennifer Wargo, M.D., elected Fellow of the AACR AcademyImmunotherapy pioneer James P. Allison, Ph.D., honored with Award for Lifetime Achievement in Cancer Research NewsletterStay up to date on the most recent and practice-changing oncology dataSubscribe Now! Related ContentGiants of Cancer Care Announces the 14th Annual Class of Inductees ByOncLiveMay 8th 2026OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer UpdatesByOncLive StaffMay 8th 2026OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026ByCaroline SeymourMay 8th 2026Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026ByAshling Wahner May 8th 2026First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCCByAshling Wahner May 8th 2026 Latest CMEVideoProactive Adverse Event Management for HER2+ BTC TreatmentsRahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCOView moreMultimediaCommunity Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for MelanomaYana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR View moreVirtual EventWisconsin Association of Hematology and Oncology1 Session is Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology SocietySeth A. Wander, MD, PhD; Girish Kunapareddy, MDView moreVirtual EventArkansas Association of Cancer Professionals2 Sessions are Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology SocietySeth A. Wander, MD, PhD; Kit Lu, MDView moreVideo19th Annual New York GU Cancers Congress®Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MDView moreIn-Person + Virtual EventGo to PER in ChicagoMay 29-31, 2026View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice SocietySeth A. Wander, MD, PhD; Kamel Abou Hussein, MDView moreVirtual EventKansas Society of Clinical Oncology1 Session is Available!View moreVideoA Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCRView moreVideoEvolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular TestingEileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPHView moreVideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoTumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLCBalazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MDView moreVideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic ApproachesRami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MDView moreVideoPER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging StrategiesJonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhDView moreVideoMedical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted TherapiesVinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MSView moreVideoMedical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoMedical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 DysregulationRebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhDView moreVideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical InsightsGail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHSView moreVideoMedical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast CancerWilliam J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhDView moreVideoGI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal CancerJohn H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MDView moreVideoBreast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer TreatmentJoyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCOView moreMultimediaEstablishing the Rationale for ADC and ICI Combinations in TNBCVirginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCOView moreMultimediaBreaking Down the Rationale for Targeting TROP2 in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaDissecting Clinical Trial and Real-World Data for ADCs in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaEvaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MDView moreAudioBreaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MSView moreVideoOptimizing Treatment for Biliary Tract CancersGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoCross-Disease Integration of Immunotherapy InnovationsGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreAudioPractical Considerations and Future Directions for New Treatment Strategies in SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhDView moreMultimediaExpert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DScView moreVideoBroadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular CarcinomaGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreMultimediaPER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – NursingAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCOView moreMultimediaExpert Roundtable and Panel Discussions: Current and Future Landscape of TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCOView moreVideoShow Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast CancerAna C. Garrido-Castro, MD; Pedram Razavi, MD, PhDView moreAudioNavigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New OptionsRahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhDView moreVideoMedical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk AssessmentJason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MDView moreMultimediaReady for Radioligand Therapy? Patient Selection and Sequencing SimplifiedJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaWorking Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary CareJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaBURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate CancerJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaImaging Matters: Decoding PSMA PET for Better Decision-MakingJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaRadioligand Therapy 101: The Science Behind the StrategyJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreVideo Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease ContinuumTina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhDView moreMultimediaCommunity Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary TeamYana G. Najjar, MD; Sapna Patel, MDView moreVideoA New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCsSandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHSView moreVideoNavigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVOSriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRSView moreVideoEnhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment StrategiesAna Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACPView moreVideo(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient OutcomesMichelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPOView more Trending on OncLive1Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer2ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies3FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease4Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts Warn5Mentorship Is Key to Advance the Next Generation of Oncology Researchers